Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides

M. N. Saleh, C. F. LeMaistre, T. M. Kuzel, F. Foss, L. C. Platanias, G. Schwartz, M. Ratain, A. Rook, C. O. Freytes, F. Craig, J. Reuben, M. W. Sams, J. C. Nichols

Research output: Contribution to journalArticle

108 Scopus citations

Abstract

Background: DAB389IL-2 is a novel fusion toxin that retargets the cytotoxic A-chain of diphtheria toxin to interleukin-2 (IL-2) receptor- expressing tumors. Objective: The purpose of this phase I trial was to study the toxicity, maximum tolerated dose, and clinical efficacy of DAB389IL-2 in IL-2 receptor expressing lymphoproliferative malignancies, including cutaneous T-cell lymphoma. Methods: DAB389IL-2 was administered intravenously daily for 5 days every 3 weeks. Dose escalation occurred between patient groups. Patients were monitored for laboratory and clinical toxicity, kinetics, immune response, and clinical efficacy. Results: Thirty- five patients with cutaneous T-cell lymphoma (including 30 patients with mycosis fungoides) were treated. Previously, conventional therapy had not worked for 34 of the patients. Thirteen patients (37%) achieved an objective response, including a complete response in five patients (14%). Complete response was achieved in patients with extensive erythroderma and tumor stage mycosis fungoides. Adverse events consisted of reversible fever/chills, hypotension, nausea/vomiting, and elevation of hepatic transaminase. Doses of less than 31 μg/kg per day were well tolerated. Clinical responses were observed at all dose levels. Conclusion: DAB389IL-2 is well tolerated at doses of less than 31 μg/kg per day, and it induced clinical responses in previously treated mycosis fungoides, providing evidence for the antitumor activity of this molecule.

Original languageEnglish (US)
Pages (from-to)63-73
Number of pages11
JournalJournal of the American Academy of Dermatology
Volume39
Issue number1
DOIs
StatePublished - Jan 1 1998

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Antitumor activity of DAB<sub>389</sub>IL-2 fusion toxin in mycosis fungoides'. Together they form a unique fingerprint.

Cite this